HomeCompareGTHX vs FCPT

GTHX vs FCPT: Dividend Comparison 2026

GTHX yields 27.93% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTHX wins by $68.3K in total portfolio value
10 years
GTHX
GTHX
● Live price
27.93%
Share price
$7.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$117.4K
Annual income
$14,597.27
Full GTHX calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — GTHX vs FCPT

📍 GTHX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTHXFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTHX + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTHX pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTHX
Annual income on $10K today (after 15% tax)
$2,374.30/yr
After 10yr DRIP, annual income (after tax)
$12,407.68/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, GTHX beats the other by $7,498.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTHX + FCPT for your $10,000?

GTHX: 50%FCPT: 50%
100% FCPT50/50100% GTHX
Portfolio after 10yr
$83.2K
Annual income
$10,186.28/yr
Blended yield
12.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GTHX right now

GTHX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$4.50
-37.2% upside vs current
Range: $3.00 — $6.00
Altman Z
-8.1
Piotroski
2/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTHX buys
0
FCPT buys
0
No recent congressional trades found for GTHX or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTHXFCPT
Forward yield27.93%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$117.4K$49.1K
Annual income after 10y$14,597.27$5,775.28
Total dividends collected$77.9K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$4.50$27.00

Year-by-year: GTHX vs FCPT ($10,000, DRIP)

YearGTHX PortfolioGTHX Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$13,493$2,793.30$11,401$700.92+$2.1KGTHX
2$17,960$3,522.50$13,064$864.84+$4.9KGTHX
3$23,599$4,381.91$15,051$1,072.48+$8.5KGTHX
4$30,632$5,381.06$17,442$1,337.22+$13.2KGTHX
5$39,305$6,527.76$20,340$1,677.08+$19.0KGTHX
6$49,884$7,827.82$23,880$2,116.57+$26.0KGTHX
7$62,660$9,284.80$28,241$2,689.36+$34.4KGTHX
8$77,946$10,899.91$33,660$3,442.07+$44.3KGTHX
9$96,075$12,671.94$40,456$4,439.95+$55.6KGTHX
10$117,397$14,597.27$49,063$5,775.28+$68.3KGTHX

GTHX vs FCPT: Complete Analysis 2026

GTHXStock

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Full GTHX Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this GTHX vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTHX vs SCHDGTHX vs JEPIGTHX vs OGTHX vs KOGTHX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.